Literature DB >> 33623132

Scenario analysis for programmatic tuberculosis control in Bangladesh: a mathematical modelling study.

Md Abdul Kuddus1,2,3, Michael T Meehan4, Md Abu Sayem5, Emma S McBryde4,6.   

Abstract

Tuberculosis (TB) is a major public health problem in Bangladesh. Although the National TB control program of Bangladesh is implementing a comprehensive expansion of TB control strategies, logistical challenges exist, and there is significant uncertainty concerning the disease burden. Mathematical modelling of TB is considered one of the most effective ways to understand the dynamics of infection transmission and allows quantification of parameters in different settings, including Bangladesh. In this study, we present a two-strain mathematical modelling framework to explore the dynamics of drug-susceptible (DS) and multidrug-resistant (MDR) TB in Bangladesh. We calibrated the model using DS and MDR-TB annual incidence data from Bangladesh from years 2001 to 2015. Further, we performed a sensitivity analysis of the model parameters and found that the contact rate of both strains had the largest influence on the basic reproduction numbers [Formula: see text] and [Formula: see text] of DS and MDR-TB, respectively. Increasingly powerful intervention strategies were developed, with realistic impact and coverage determined with the help of local staff. We simulated for the period from 2020 to 2035. Here, we projected the DS and MDR-TB burden (as measured by the number of incident cases and mortality) under a range of intervention scenarios to determine which of these scenario is the most effective at reducing burden. Of the single-intervention strategies, enhanced case detection is the most effective and prompt in reducing DS and MDR-TB incidence and mortality in Bangladesh and that with GeneXpert testing was also highly effective in decreasing the burden of MDR-TB. Our findings also suggest combining additional interventions simultaneously leads to greater effectiveness, particularly for MDR-TB, which we estimate requires a modest investment to substantially reduce, whereas DS-TB requires a strong sustained investment.

Entities:  

Year:  2021        PMID: 33623132     DOI: 10.1038/s41598-021-83768-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  4 in total

1.  The construction of next-generation matrices for compartmental epidemic models.

Authors:  O Diekmann; J A P Heesterbeek; M G Roberts
Journal:  J R Soc Interface       Date:  2009-11-05       Impact factor: 4.118

Review 2.  Global scale-up of the programmatic management of multidrug-resistant tuberculosis.

Authors:  Charles L Daley
Journal:  Indian J Tuberc       Date:  2014-04

3.  What does a mathematical model tell about the impact of reinfection in korean tuberculosis infection?

Authors:  Sara Kim; Seoyun Choe; Junseong Kim; Sanga Nam; Yeon Shin; Sunmi Lee
Journal:  Osong Public Health Res Perspect       Date:  2014-02-05

Review 4.  Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda.

Authors:  Carole D Mitnick; Carly A Rodriguez; Marita L Hatton; Grania Brigden; Frank Cobelens; Martin P Grobusch; Robert Horsburgh; Christoph Lange; Christian Lienhardt; Eyal Oren; Laura J Podewils; Barbara Seaworth; Susan van den Hof; Charles L Daley; Agnes C Gebhard; Fraser Wares
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

  4 in total
  2 in total

1.  Performance of WHO-Endorsed Rapid Tests for Detection of Susceptibility to First-Line Drugs in Patients with Pulmonary Tuberculosis in Bangladesh.

Authors:  S M Mazidur Rahman; Md Fahim Ather; Rumana Nasrin; Mohammad Ariful Hoque; Razia Khatun; Tanjina Rahman; Mohammad Khaja Mafij Uddin; Shahriar Ahmed; Sayera Banu
Journal:  Diagnostics (Basel)       Date:  2022-02-05

2.  Mathematical analysis of a two-strain tuberculosis model in Bangladesh.

Authors:  Md Abdul Kuddus; Emma S McBryde; Adeshina I Adekunle; Lisa J White; Michael T Meehan
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.